A recent study by Zeng et al. (2016) revealed that MLN0128, a second‐generation mTOR kinase inhibitor currently in clinical development, might promote AML stem/progenitor cell killing through selective blockade of AKT/mTOR signaling. The gene discussed is MTOR; the disease is acute myeloid leukemia.